Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors

This publication has 87 references indexed in Scilit:

• A Landscape of Driver Mutations in Melanoma
  Cell, 2012
• PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
  The Journal of Immunology, 2012
• Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
  New England Journal of Medicine, 2011
• RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it
  Journal of Clinical Investigation, 2011
• CD47
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2008
• Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo
  Proceedings of the National Academy of Sciences, 2007
• MEK1-ERK2 Signaling Pathway Protects Myocardium From Ischemic Injury In Vivo
  Circulation, 2004
• c-Raf/MEK/ERK Pathway Controls Protein Kinase C-mediated p70S6K Activation in Adult Cardiac Muscle Cells
  Journal of Biological Chemistry, 2002
• The MEKK-JNK Pathway Is Stimulated by α1-Adrenergic Receptor and Ras Activation and Is Associated with in Vitro and in Vivo Cardiac Hypertrophy
  Journal of Biological Chemistry, 1997
• Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
  Science, 1995